(1S)-1,5-anhydro-1-[3-(1-benzothiophen-2-ylmethyl)-4-chlorophenyl]-D-glucitol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1S)-1,5-anhydro-1-[3-(1-benzothiophen-2-ylmethyl)-4-chlorophenyl]-D-glucitol
• 英文别名: 3-(benzo[b]thiophen-2-ylmethyl)-4-chloro-1-(β-D-glucopyranosyl)benzene；(2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-chlorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
• 化学式: C₂₁H₂₁ClO₅S
• 分子量: 420.914
• InChiKey: BDTYVRWUCYRNFY-RQXATKFSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  118
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-(benzo[b]thiophen-2-ylmethyl)-4-chloro-1-(1-α-methoxy-β-D-glucopyranosyl)benzene 在 三氟化硼乙醚 三乙基硅烷 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 (1S)-1,5-anhydro-1-[3-(1-benzothiophen-2-ylmethyl)-4-chlorophenyl]-D-glucitol
  参考文献：
  名称：

  Novel SGLT inhibitors

  摘要：

  化合物的新颖结构式（A）或其药学上可接受的盐： 其中符号如权利要求中所定义，这些化合物可用作SGLT抑制剂，用于治疗糖尿病及相关疾病。

  公开号：

  US20080027014A1

文献信息

• Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus
  作者：Masakazu Imamura、Keita Nakanishi、Takayuki Suzuki、Kazuhiro Ikegai、Ryota Shiraki、Takashi Ogiyama、Takeshi Murakami、Eiji Kurosaki、Atsushi Noda、Yoshinori Kobayashi、Masayuki Yokota、Tomokazu Koide、Kazuhiro Kosakai、Yasufumi Ohkura、Makoto Takeuchi、Hiroshi Tomiyama、Mitsuaki Ohta

  DOI：10.1016/j.bmc.2012.03.051

  日期：2012.5

  several compounds, the benzothiophene derivative (14a) was found to have potent inhibitory activity against SGLT2 and good selectivity versus SGLT1. Through further optimization of 14a, a novel benzothiophene derivative (14h; ipragliflozin, ASP1941) was discovered as a highly potent and selective SGLT2 inhibitor that reduced blood glucose levels in a dose-dependent manner in diabetic models KK-Ay mice and

  合成了一系列具有各种杂芳族化合物的C-葡萄糖苷，并评估了其对SGLT的抑制活性。在筛选了几种化合物后，发现苯并噻吩衍生物（14a）对SGLT2具有有效的抑制活性，并且对SGLT1具有良好的选择性。通过进一步优化14a，发现了一种新型的苯并噻吩衍生物（14h ;伊格列净，ASP1941）是一种高效且选择性的SGLT2抑制剂，可在糖尿病模型KK-A y小鼠和STZ大鼠中以剂量依赖的方式降低血糖水平。
• C-glycoside derivatives and salts thereof
  申请人：Imamura Masakazu

  公开号：US20070161787A1

  公开（公告）日：2007-07-12

  The present invention provides C-glycoside derivatives and salts thereof, wherein B ring is bonded to A ring via —X— and A ring is directly bonded to the glucose residue, and it is usable as a Na + -glucose cotransporter inhibitor, especially for a therapeutic and/or preventive agent for diabetes such as insulin-dependent diabetes (type 1 diabetes) and insulin-independent diabetes (type 2 diabetes), as well as diabetes related diseases such as an insulin-resistant diseases and obesity.

  本发明提供了C-糖苷衍生物及其盐，其中B环通过—X—与A环连接，而A环直接与葡萄糖残基连接。该化合物可用作Na+-葡萄糖共转运体抑制剂，特别适用于治疗和/或预防糖尿病，如胰岛素依赖性糖尿病（1型糖尿病）和胰岛素非依赖性糖尿病（2型糖尿病），以及与糖尿病相关的疾病，如胰岛素抵抗性疾病和肥胖症。
• GLUCOPYRANOSIDE COMPOUND
  申请人：NOMURA Sumihiro

  公开号：US20120058941A1

  公开（公告）日：2012-03-08

  A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH 2 ) n — (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

  该化合物的分子式为：其中环A和环B分别为：（1）环A为可选取代的不饱和单环杂环，环B为可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环；（2）环A为可选取代的苯环，环B为可选取代的不饱和单环杂环或可选取代的不饱和融合杂双环；或（3）环A为可选取代的不饱和融合杂双环，环B可独立地为可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环；X为碳原子或氮原子；Y为—（CH2）n—（n为1或2）；或其药学上可接受的盐或前药。
• C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF
  申请人：Astellas Pharma Inc.

  公开号：EP1609785B1

  公开（公告）日：2016-02-03
• Novel compounds having inhibitory activity against sodium-dependant glucose transporter
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2896397B1

  公开（公告）日：2017-09-06